Literature DB >> 32504600

Transapical Aspiration of a Mitral Mass With the AngioVac System on a Beating Heart.

Gino Gerosa1, Lorenzo Longinotti1, Lorenzo Bagozzi1, Augusto D'Onofrio1, Fabio Zanella1, Demetrio Pittarello1, Vincenzo Tarzia2.   

Abstract

The AngioVac System has already proved to be effective and safe in the treatment of thrombotic and endocarditic formations concerning the venous district and the tricuspid valve. We describe an innovative use of the AngioVac System to treat a left-sided heart mass. In a high-surgical-risk patient, we used a micro-invasive transapical access and a modified extracorporeal membrane oxygenation circuit to remove the mass from the mitral bioprosthesis without having to replace it. Further experiences are required to confirm the safety of this technique in high-risk patients.
Copyright © 2020 The Society of Thoracic Surgeons. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2020        PMID: 32504600     DOI: 10.1016/j.athoracsur.2020.04.051

Source DB:  PubMed          Journal:  Ann Thorac Surg        ISSN: 0003-4975            Impact factor:   4.330


  3 in total

1.  Percutaneous Aspiration (AngioVac) of a Mitral Valve Vegetation followed by a Transcatheter Mitral Valve-in-Valve Intervention.

Authors:  Jack Xu; Shravan Turaga; Jay Bhama; Srikanth Vallurupalli; Gaurav Dhar
Journal:  Methodist Debakey Cardiovasc J       Date:  2022-07-11

2.  Endovascular Treatment of Right Heart Masses Utilizing the AngioVac System: A 6-Year Single-Center Observational Study.

Authors:  Aashish Katapadi; Lauren Richards; William Fischer; Suhail Q Allaqaband; Tanvir Bajwa; M Fuad Jan
Journal:  J Interv Cardiol       Date:  2021-10-31       Impact factor: 2.279

3.  Vacuum-Implemented Removal of Lead Vegetations in Cardiac Device-Related Infective Endocarditis.

Authors:  Vincenzo Tarzia; Matteo Ponzoni; Giuseppe Evangelista; Chiara Tessari; Emanuele Bertaglia; Manuel De Lazzari; Fabio Zanella; Demetrio Pittarello; Federico Migliore; Gino Gerosa
Journal:  J Clin Med       Date:  2022-08-07       Impact factor: 4.964

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.